IPF
Clinical trials for IPF explained in plain language.
Never miss a new study
Get alerted when new IPF trials appear
Sign up with your email to follow new studies for IPF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung scarring: HSK44459 enters final trial phase
Disease control Not yet recruitingThis study tests a new tablet, HSK44459, for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 420 adults aged 40 and older will receive either the drug or a placebo for 52 weeks. The main goal is to see if the drug he…
Matched conditions: IPF
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New inhaled drug for lung disease tested in healthy people first
Knowledge-focused Not yet recruitingThis early-stage study tests a new inhaled drug called RC010 in 42 healthy adults in China. The main goal is to check if it is safe and how the body processes it. This drug is being developed for a serious lung condition called idiopathic pulmonary fibrosis (IPF), but this study …
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Nanjing Reju Therapeutics Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Healthy volunteers to test experimental lung disease drug
Knowledge-focused Not yet recruitingThis early-stage study tests a new drug, HW252001, in 98 healthy adults aged 18 to 55. The goal is to check the drug's safety and how the body processes it, not to treat any disease. Participants will receive either the drug or a placebo, and researchers will monitor for side eff…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC